FDA Inspection 1119387 — OMRIX Biopharmaceuticals Ltd.
The FDA completed an inspection of OMRIX Biopharmaceuticals Ltd. on Feb 24, 2020 in Ramat Gan. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Biologics.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Feb 24, 2020
- Fiscal Year
- 2020
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Ramat Gan (Israel)